Earlier this month, the Drug Controller General of India (DCGI) had given its nod to Oxford/AstraZeneca’s Covishield vaccine which is manufactured by the Serum Institute of India, and the indigenously developed Covaxin from Bharat Biotech for ‘restricted emergency use’.
The vaccine will first be administered to an estimated one crore healthcare workers, and around two crore frontline workers, and then to persons above 50 years of age, followed by persons younger than 50 years of age with associated comorbidities.
Following the launch of the drive, Bharat Biotech, the manufacturer of Covaxin, said that the company will pay compensation to vaccine recipients in case of any serious adverse effects experienced after receiving the shot. In the consent form to be signed by the vaccine recipients, Bharat Biotech said, “In case of any adverse events or serious adverse events, you will be provided medically recognised standard of care in the government designated and authorised centres/hospitals.”
The statement from the Covaxin manufacturer comes after questions were raised over the efficacy of the vaccine as its phase 3 clinical trials are yet to be completed.